Physician

Courtney M Bellomo, M.D.

According to 2025 Medicare claims, Courtney Bellomo, M.D. (NPI: 1790929529) practices medical oncology in the Albany-Schenectady-Troy, NY market, with the plurality of this provider's patient population coming from Albany, NY. This provider's primary affiliated billing organization is NEW YORK ONCOLOGY HEMATOLOGY, P.C. (NPI: 1609863448; TIN: 141799724) and primary practice location at 12208-3412. Bellomo is affiliated with the Bassett Accountable Care Partners, LLC (ACO ID: A2612), participating under the MSSP model.

Bellomo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 551 traditional Medicare patients, billed 68,723 HCPCS/CPT codes, and received $1,191,775 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,123 prescription claims across 144 beneficiaries totaling $3,562,909 in drug costs, led by Lenalidomide (Lenalidomide). 2022 DME data shows 11 claims. Open Payments data shows 8 records totaling $32,123. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $534,141 and ending at $1,191,775. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $619,158 and ending at $3,562,909. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $586 and ending at $1,287.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	495	39,797	$534,141
2016	525	43,738	$861,515
2017	508	46,732	$820,545
2018	561	50,119	$1,001,639
2019	502	57,836	$1,108,814
2020	316	19,353	$419,488
2021	368	22,585	$497,278
2022	416	46,749	$647,032
2023	492	52,652	$792,544
2024	551	68,723	$1,191,775

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	104	602	$619,158
2016	129	1,153	$1,541,462
2017	162	1,157	$2,392,512
2018	178	1,532	$4,092,480
2019	171	1,575	$5,067,634
2020	122	1,101	$2,678,846
2021	136	1,205	$3,496,117
2022	167	1,367	$2,624,032
2023	152	1,203	$2,918,096
2024	144	1,123	$3,562,909

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	145	$11,513
2019	N/R	141	$5,818
2020	N/R	146	$7,148
2021	N/R	134	$8,892
2022	N/R	11	$204
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	206	244	$60
80053	Blood test, comprehensive group of blood chemicals	306	467	$10
36415	Insertion of needle into vein for collection of blood sample	329	579	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	331	553	$8
83615	Lactate dehydrogenase (enzyme) level	188	255	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	63	1,743	$734,319
Empaveli	Pegcetacoplan	13	364	$498,012
Jakafi	Ruxolitinib Phosphate	25	780	$436,757
Revlimid	Lenalidomide	24	658	$416,300
Imbruvica	Ibrutinib	27	780	$310,564

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$123	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	7	$32,000	Celgene Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Courtney M. Bellomo, M.D.?

Tedicare shows public-source Medicare data for Courtney M. Bellomo, M.D. (NPI 1790929529), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Courtney M. Bellomo, M.D. have ACO affiliation data?

Courtney M. Bellomo, M.D. is shown with ACO affiliation data for Bassett Accountable Care Partners, LLC (MSSP, ACO ID A2612).

What billing organization is linked to Courtney M. Bellomo, M.D.?

Courtney M. Bellomo, M.D. is linked to NEW YORK ONCOLOGY HEMATOLOGY, P.C. (billing NPI 1609863448) in the available physician profile data.

Does Courtney M. Bellomo, M.D. have Open Payments data?

Courtney M. Bellomo, M.D. has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.